
In spite of raised expectations for 2013, which exceeded the estimates of most analysts, Nordea does not have a lot of faith in Eli Lilly.
“It is certainly positive, but ahead – in December – lies he patent expiration of one of their best selling products, the antidepressant Cymbelta, which produced a turnover of 4.8 billion dollars in 2012. That is a major uncertainty factor from the share and – being relatively high priced – we see better opportunities elsewhere in the sector,” the bank writes in its morning report Monday.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app